Comparison between lergotrile and bromocriptine in parkinsonism.

Area of Science:

• Neurology
• Pharmacology

Background:

• Idiopathic parkinsonism is a neurodegenerative disorder characterized by motor deficits.
• Ergot derivatives like bromocriptine and lergotrile are explored as therapeutic agents.

Purpose of the Study:

• To compare the therapeutic and adverse effects of bromocriptine and lergotrile in patients with idiopathic parkinsonism.
• To determine optimal dosage ranges and identify factors influencing drug choice.

Main Methods:

• A comparative study evaluating bromocriptine and lergotrile at low (50 mg/day) and high (150 mg/day) dosages.
• Assessment of neurological deficits, therapeutic response, and adverse effects, including hypotension and dyskinesia.
• Comparison with levodopa and carbidopa treatment regimens.

Main Results:

• Both drugs showed similar therapeutic profiles, with improved neurological deficits at combined daily doses of 80-150 mg ergot derivatives with levodopa/carbidopa.
• Lergotrile induced transient hypotension; bromocriptine caused more dyskinesia at higher doses.
• Adverse effects increased with dosages over 100 mg/day, with optimal results at 50-100 mg/day for each ergot derivative.

Conclusions:

• Bromocriptine and lergotrile possess comparable efficacy to levodopa plus carbidopa for Parkinson's treatment.
• Optimal therapeutic outcomes are often achieved by combining submaximal doses of levodopa with ergot derivatives.
• Drug selection may depend on cost (bromocriptine) and hepatotoxicity concerns (lergotrile).